Login
Companies $GNLX
$1.89 -$0.03 (1.56%) After hours
GENELUX Corp logo

GENELUX Corp

genelux.com

What Do They Do?

Develops virus-based cancer treatment candidates for patients with difficult-to-treat tumors, led by Olvi-Vec.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $32.1M in FY2025.

Operating income, FY2025
−415175% of revenue
▼ −5% (Loss) vs FY2024 (−$31.7M, −396200%)
Net income, FY2025
−401813% of revenue
▼ −8% (Loss) vs FY2024 (−$29.9M, −373363%)
Free cash flow, FY2025
−329575% of revenue
▼ −22% (Loss) vs FY2024 (−$21.6M, −270113%)

Who Do They Compete With?

Competes with Abbvie, Eisai, Roche/Genentech, Merck, GSK, AstraZeneca, Tolmar, Verstem Oncology, Corcept Therapeutics, Novartis, Pfizer, Johnson & Johnson, Eli Lilly, Bristol Myers Squibb, and Amgen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support